CNS Pharmaceuticals, Inc.
NASDAQ Capital MarketTotal Valuation
CNS Pharmaceuticals, Inc. carries a market capitalization of 6.99M, placing it among publicly traded companies globally.
| Market Cap | 6.99M |
| Enterprise Value | N/A |
Share Statistics
CNS Pharmaceuticals, Inc. currently has 1.46M shares outstanding.
| Shares Outstanding | 1.46M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.38 |
| P/TBV Ratio | 0.38 |
| P/FCF Ratio | -0.96 |
| P/OCF Ratio | -0.96 |
Financial Position
CNS Pharmaceuticals, Inc. maintains a current ratio of 5.86, meaning it holds 5.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 5.86 |
| Quick Ratio | 5.35 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -1,130.57 |
Financial Efficiency
| Return on Equity (ROE) | -106.62 |
| Return on Assets (ROA) | -91.64 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
CNS Pharmaceuticals, Inc.'s stock has declined approximately -47.75956% over the past 52 weeks. The 50-day moving average sits at 5.45, while the 200-day moving average is 4.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -47.75956% |
| 50-Day Moving Average | 5.45 |
| 200-Day Moving Average | 4.63 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -16.90M, while operating income came in at -16.91M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -16.91M |
| Pretax Income | -16.70M |
| Net Income | -16.70M |
| EBITDA | -16.90M |
| EBIT | -16.91M |
| Earnings Per Share (EPS) | -6.21 |
Balance Sheet
Total book value stands at 18.20M, with working capital of 18.19M providing operational flexibility.
| Cash & Cash Equivalents | 19.99M |
| Total Debt | N/A |
| Net Debt | -19.98M |
| Equity (Book Value) | 18.20M |
| Book Value Per Share | 12.45 |
| Working Capital | 18.19M |
Cash Flow
CNS Pharmaceuticals, Inc. produced -13.41M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -13.42M - equivalent to -4.99 per share.
| Operating Cash Flow | -13.41M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -13.42M |
| FCF Per Share | -4.99 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -304.86 |
| FCF Yield | -104.20 |
Stock Splits
CNS Pharmaceuticals, Inc.'s most recent stock split took place on July 22, 2025 with a 12:1 split ratio.
| Last Split Date | 7/22/2025 |
| Split Ratio | 12:1 |
Scores
CNS Pharmaceuticals, Inc. posts an Altman Z-Score of -7.31, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.31 |